NCT04364373
D2 vs D3 Lymph Node Dissection for Left Colon Cancer
Recruiting · Not Applicable · Russian Society of Colorectal Surgeons · registry updated 2026-08-17
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.
Inclusion
- Agreement of the patient to participate in trial
- Colon cancer (only adenocarcinoma )
- The tumor located between the splenic flexure and rectosigmoid junction
- Tolerance of chemotherapy
Exclusion
- сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder)
- Preoperative complications of the tumor (perforation and full bowel 3. obstruction)
- Previous radiotherapy or chemotherapy
- Synchronous or metachronous tumors
- Women during Pregnancy or breast feeding period